GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients
BOSTON, May 4, 2015 /PRNewswire-USNewswire/ -- GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced that it has initiated dosing of Alzheimer's patients in a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a potential disease-modifying treatment. GliaCure's innovative approach to treating Alzheimer's disease is innovative in that it both promotes the clearance of amyloid and stimulates anti-inflammatory actions through a single target, an approach that has recently been supported by research studies from independent groups.
"We are optimistic that our Phase 1b study will demonstrate that GC021109 is both safe and well tolerated in early stage Alzheimer's patients," stated GliaCure board member Joe Zakrzewski. "Data from this study will prove invaluable as we move forward with the design our Phase 2 trial."
GliaCure's Phase 1b trial, which began recruiting volunteers in February 2015, includes multiple ascending dosing of 36 subjects and is intended to demonstrate safety and tolerability of GC021109. The study is co-funded by the Alzheimer's Drug Discovery Foundation (ADDF). More information about the study can be found at https://clinicaltrials.gov/ct2/show/NCT02386306?term=gliacure&rank=1.
About GliaCure, Inc.
GliaCure is a privately held company that is pioneering the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company's approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery. The dual phagocytic and anti-inflammatory actions of the GliaCure's lead clinical candidate, GC021109, have the potential to serve as a disease-modifying treatment for Alzheimer's disease and to affect other disorders, including psoriasis, Parkinson's disease, multiple sclerosis and glaucoma. GliaCure has an exclusive license to the GC021109 compound and related technology from Tufts University. GliaCure also has a pipeline program for the development of therapeutics for astrocytic targets related to sleep disorders and depression. The company is based in Boston and is headed by Professor Philip G. Haydon, who also holds the position of Annetta and Gustav Grisard Professor and Chair of Neuroscience at Tufts University.
CONTACT: Yolande Haydon, 610-246-6012, [email protected]
SOURCE GliaCure, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article